Cargando…

Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics

Spectinamides 1599 and 1810 are lead spectinamide compounds currently under preclinical development to treat multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. These compounds have previously been tested at various combinations of dose level, dosing frequency, and route of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parmar, Keyur R., Lukka, Pradeep B., Wagh, Santosh, Temrikar, Zaid H., Liu, Jiuyu, Lee, Richard E., Braunstein, Miriam, Hickey, Anthony J., Robertson, Gregory T., Gonzalez-Juarrero, Mercedes, Edginton, Andrea, Meibohm, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305115/ https://www.ncbi.nlm.nih.gov/pubmed/37376207 http://dx.doi.org/10.3390/pharmaceutics15061759

Ejemplares similares

Primary Lung Dendritic Cell Cultures to Assess Efficacy of Spectinamide-1599 Against Intracellular Mycobacterium tuberculosis
por: Santos, Karen, et al.
Publicado: (2018)

In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics
por: Bruhn, David F., et al.
Publicado: (2015)

ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models
por: Mavroudis, Panteleimon D., et al.
Publicado: (2019)

Spectinamides: A New Class of Semisynthetic Anti-Tuberculosis Agents that Overcome Native Drug Efflux
por: Lee, Richard E., et al.
Publicado: (2014)

Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis
por: Ayyar, Vivaswath S., et al.
Publicado: (2022)

Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models
por: Robertson, Gregory T., et al.
Publicado: (2017)

Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients
por: Temrikar, Zaid H., et al.
Publicado: (2020)

1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model
por: Rubino, Christopher M, et al.
Publicado: (2018)

Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells
por: Midde, Narasimha M., et al.
Publicado: (2017)

Replacement of S14 Protein in Ribosomes of Zinc-Starved Mycobacteria Reduces Spectinamide Sensitivity
por: Li, Yunlong, et al.
Publicado: (2021)

Alcohol inhibits the metabolism of dimethyl fumarate to the active metabolite responsible for decreasing relapse frequency in the treatment of multiple sclerosis
por: Yang, Bing, et al.
Publicado: (2022)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
por: Kovar, Lukas, et al.
Publicado: (2020)

Exploiting Peptide Self-Assembly for the Development of Minimalistic Viral Mimetics
por: Janković, Patrizia, et al.
Publicado: (2021)

Minimalist spaces = Espacios minimalistas /
por: Mostaedi, Arian
Publicado: (2003)

PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
por: Bloomingdale, Peter, et al.
Publicado: (2022)

Minimalist Mobile Robotics
por: Connell, Jonathan
Publicado: (2012)

Development and application of a PBPK modeling strategy to support antimalarial drug development
por: Abla, Nada, et al.
Publicado: (2023)

Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases
por: Bloomingdale, Peter, et al.
Publicado: (2021)

Minimalist Approach to Perceptual Interactions
por: Lenay, Charles, et al.
Publicado: (2012)

Minimalistic Neutrino Mass Model
por: de Gouvea, Andre, et al.
Publicado: (2000)

Designing minimalist membrane proteins
por: Curnow, Paul
Publicado: (2019)

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

Physiologically based pharmacokinetic (PBPK) modeling and simulation in drug discovery and development
por: Shaik, Abdul Naveed, et al.
Publicado: (2019)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling.
por: Yang, R S, et al.
Publicado: (1998)

Development of a Human Physiologically Based Pharmacokinetic (PBPK) Toolkit for Environmental Pollutants
por: Ruiz, Patricia, et al.
Publicado: (2011)

Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator
por: Ezuruike, Udoamaka, et al.
Publicado: (2022)

Minimalistic Musings about the Standard Model
por: Korthals Altes, Chris P
Publicado: (2021)

The minimalist architectures of viroporins and their therapeutic implications()
por: OuYang, Bo, et al.
Publicado: (2014)

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects
por: Cui, Cheng, et al.
Publicado: (2021)

Building Minimalist Models for Functionalized Metal Nanoparticles
por: Brancolini, Giorgia, et al.
Publicado: (2019)

Minimalistic Cellulosome of the Butanologenic Bacterium Clostridium saccharoperbutylacetonicum
por: Levi Hevroni, Bosmat, et al.
Publicado: (2020)

Minimalist module analysis for fault detection and localization
por: Lou, Zhijiang, et al.
Publicado: (2021)

Minimalist De Novo Design of an Artificial Enzyme
por: Saikia, Jahnu, et al.
Publicado: (2022)

Minimalistic ice recrystallisation inhibitors based on phenylalanine
por: Warren, Matthew T., et al.
Publicado: (2022)

Biomolecular condensates formed by designer minimalistic peptides
por: Baruch Leshem, Avigail, et al.
Publicado: (2023)

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
por: Vossen, Michaela, et al.
Publicado: (2007)

A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application
por: Tylutki, Zofia, et al.
Publicado: (2017)

PBPK modeling of ivermectin—Considerations for the purpose of developing alternative routes to optimize its safety profile
por: Rowland Yeo, Karen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_re0jvv9p2tul9npmseej3im6gg